Skip to main content
. Author manuscript; available in PMC: 2013 Feb 6.
Published in final edited form as: Asian J Androl. 2010 Nov 22;13(2):322–325. doi: 10.1038/aja.2010.117

Table 1.

Baseline demographic and Peyronie’s disease characteristics of men with calcifications at their initial evaluation and at least one follow-up ultrasound

Overall
No PTX
PTX
P value
n % n % n %
Age (years) <40 10 14.1 1 11.1 9 14.5
40–49 14 19.7 3 33.3 11 17.7
50–59 36 50.7 5 55.6 31 50.0
60–69 11 15.5 0 0.0 11 17.7 0.44
Able to maintain an erection No 10 15.4 3 37.5 7 12.3
Yes 55 84.6 5 62.5 50 87.7 0.06
Painful erections No 27 65.9 6 85.7 21 61.8
Yes 14 34.2 1 14.3 13 38.2 0.22
PTX treatment No 9 12.7
Yes 62 87.3
Duration of PTX treatment (years. mean ± s.d.) 1.2 1.1
Duration of disease (years. mean ± s.d.) 2.1 2.5 1.7 1.3 2.1 2.7 0.69
Curvature (°) <30 12 16.9 1 11.1 11 17.7
30–59 24 33.8 4 44.4 20 32.3
≥60 12 16.9 2 22.2 10 16.1
Unknown 23 32.4 2 22.2 21 33.9 0.79
Penile deformity 30 42.9 5 55.6 25 41.0 0.41
Previous treatment for PD 63 88.7 9 100.0 54 87.1 0.25
History of penile injury 19 36.5 4 50.0 15 34.1 0.39
No. of calcifications (mean ± s.d.) 1.6 1.2 1.9 1.3 1.6 1.2 0.49
Cumulative calcified area (mm2, mean ± s.d.) 13.8 23.1 12.4 8.6 14.0 25.1 0.86

Abbreviation: PD, Peyronie’s disease; PTX, pentoxifylline; —, No treatment for Peyronie’s disease.